1000604-24-9

Upstream product

• 26307-50-6 4-bromo-2-isopropyl-phenol 
• 88-69-7 2-(1-methylethyl)phenol 
• 253329-09-8 4-bromo-2-isopropyl-1-triisopropylsilanyloxybenzene 
• 1000603-89-3 (3-isopropyl-4-triisopropylsilanyloxyphenyl)methanol 
• 124-63-0 methanesulfonyl chloride 
• 2944-47-0 o-isopropylanisole 
• 1000603-91-7 3-isopropyl-4-triisopropylsilanyloxy-benzaldehyde 

Downstream Products

• 1000604-23-8 1-(3-isopropyl-4-triisopropylsilanyloxybenzyl)-4-nitro-1H-indole 
• 1000605-77-5 ethyl N-[1-(3-isopropyl-4-triisopropylsilanyloxybenzyl)-2-methyl-1H-indol-4-yl]malonamate 
• 1000605-82-2 ethyl N-[1-(3-isopropyl-4-triisopropylsilanyloxybenzyl)-7-methyl-1H-indol-4-yl]malonamate 
• 1000602-23-2 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-1H-indol-4-yl]oxamate 
• 1000602-30-1 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]oxamate 
• 1000602-40-3 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-7-methyl-1H-indol-4-yl]oxamate 
• 1000602-31-2 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]malonamate 
• 1000602-42-5 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-7-methyl-1H-indol-4-yl]malonamate 
• 1000602-68-5 ethyl N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-5-yl]oxamate 
• 1000602-98-1 N-[1-(4-hydroxy-3-isopropylbenzyl)-1H-indol-4-yl]oxamic acid 
• 1000603-08-6 N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]oxamic acid 
• 1000603-15-5 N-[1-(4-hydroxy-3-isopropylbenzyl)-7-methyl-1H-indol-4-yl]oxamic acid 
• 1000603-09-7 N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]malonic acid 
• 1000603-16-6 N-[1-(4-hydroxy-3-isopropylbenzyl)-7-methyl-1H-indol-4-yl]malonic acid 

Relevant academic research and scientific papers

Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists

The design, synthesis, and structure activity relationships for a novel series of indoles as potent, selective, thyroid hormone receptor β (TRβ) agonists is described. Compounds with >50× binding selectivity for TRβ over TRα were generated and evaluation of compound 1c from this series in a model of dyslipidemia demonstrated positive effects on plasma lipid endpoints in vivo.

Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole- based thyroid hormone receptor β agonists

A series of 1-benzylindole-based TRβ agonists were prepared and evaluated. Compounds 11b′ and 11c′ were found to have cholesterol-lowering in a rat model with marginal effects on cardiac function and HPT axis. The present work illustrates the potential use of indoles as inner ring isosteres.

NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF

An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].